FDA Approves Cheetah Reliant(TM) for Noninvasive Cardiac Output Monitoring (NICOM(R))

FDA Approves Cheetah Reliant(TM) for Noninvasive Cardiac Output Monitoring
(NICOM(R))
Cheetah Medical Inc. Introduces New System to Measure Accurately, and
Non-Invasively Patients' Cardiac Output and Other Hemodynamic Parameters

INDIANAPOLIS, Indiana, January 22 /PRNewswire/ -- Cheetah Medical Inc.
announces the U.S. Food and Drug Administration (FDA) approved for marketing
the Reliant, a highly accurate, portable cardiac output monitor which
provides a noninvasive window to cardiac and hemodynamic function. The
Reliant monitor is powered by Cheetah's unique, patented BIOREACTANCE(R)
Technology, which has been used effectively in over 1,000 patients in various
clinical settings including hemodynamic monitoring, heart failure,
perioperative care, hemodialysis and stress testing.
About the Reliant technology
Reliant harnesses the innovative NICOM(R) system which combines
traditional impedance technology with BIOREACTANCE(R) Technology. Traditional
bioimpedance analyzes changes in voltage of electrical currents traversing
the patient's chest, while BIOREACTANCE also analyzes frequency related
effects. NICOM's hybrid analysis helps deal with electrical noise
interference, patient movement, respiration and electrode misplacement. As a
result, NICOM enables a highly precise, accurate and responsive measurement
of cardiac function and hemodynamic status not available with other
modalities. This can be likened to improved quality of Frequency Modulation
(FM) versus traditional Amplitude Modulation (AM).
Cardiac Output Monitoring
Cardiac output monitoring has been shown in the context of specific
treatment algorithms to reduce morbidity, mortality and length of hospital
stay in a number of conditions including perioperative care, intensive care
and trauma while also providing clinical value in heart failure and dialysis.
Those conditions represent major ailments with significant associated costs.
However, leading cardiac output modalities are invasive and costly while
other approaches have not provided enough accuracy. Consequently, Cheetah
Medical believes that cardiac output is not obtained in millions of cases per
year where it can be of value and that NICOM is the solution physicians have
been waiting for.
"Across the world", Yoav Avidor, M.D., Chief Executive Officer of Cheetah
Medical Inc. says, "the healthcare environment struggles to provide quality
care to an aging population while dealing with efficiency and economic
constraints. There is a global push to reduce invasive, costly procedures
that can lead to complications and require a highly skilled physician to
deploy. Hospitals seek better solutions in terms of efficiency, cost and
scalability to more patients who can be treated in less acute settings,
without impacting quality of care. Reliant can help physicians and hospitals
do just this while maintaining and potentially improving quality of care."
Pierre Squara, MD, from Clinique Ambroise Pare, Paris, France who
recently published research on 110 surgical patients monitored with NICOM as
compared to the invasive thermodilution gold-standard, says, "In the
intensive care unit, accurate cardiac output empowers common, critical
decisions, for example optimization of fluid management, a key goal with high
impact on outcomes. Existing techniques which we have historically used
required vascular access through large veins or arteries. This took valuable
time, sometimes let to complications and higher costs which my hospital is
increasingly sensitive to. The introduction of a simple, non-invasive device
to attain accurate measurements is a major advance in intensive care
medicine. "
US General Manager Laura Rector stated, "We believe that with Reliant
healthcare professionals see a device that can deliver a new standard of
care. The uniqueness of this technology lies in its proven ability to provide
accurate, reliable, affordable and completely non-invasive information, even
during patient movement, in environments with significant electrical noise
and under highly challenging clinical circumstances. Ultimately, if you can
evaluate the health of a patient's heart accurately in non-invasive fashion
with only a few sticker electrodes, the question becomes not when would you
want to use the Reliant, but why wouldn't you use it?"
About the Company
Cheetah Medical is a privately held company with offices in Israel,
Indianapolis, Indiana and the UK. Cheetah Medical is preparing to launch its
sales and marketing activities for the US and European markets.
For more information visit http://www.cheetah-medical.com or e-mail
cheetah@cheetah-medical.com.
SOURCE Cheetah Medical Inc.

For more information visit http://www.cheetah-medical.com or e-mail
cheetah@cheetah-medical.com